Opaleye Management Inc., 10% Owner at Grace Therapeutics, Inc. (GRCE), bought 60,490 shares at $2.04 ($124K) on 2026-10-01, disclosed to the SEC on 2026-10-05.
Opaleye Management Inc. executed the largest insider purchase in the company's history, acquiring 38,796 shares for $78,961.49, signaling strong conviction in the stock's value despite recent underperformance.
The stock is trading at $2.04, down 4.67% over the last 5 days and 19.37% over the last 90 days, placing it 20.62% below its 52-week high of $2.57.
Insider cluster momentum: This is the largest insider purchase ever recorded for GRCE, a significant signal of institutional conviction.
Short interest risk: The stock has a short interest of 9.69% of the float, indicating notable speculative positioning that could drive volatility.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.04 | 38,796 | $79K | 63.8% |
| 2 | $2.07 | 20,000 | $41K | 33.4% |
| 3 | $2.06 | 1,694 | $3K | 2.8% |
| Total | $2.05 avg | 60,490 | $124K | 100% |
| Filing → |
| GRCE | BUY | 2026-10-01 | $16K | — | Filing → |
| GRCE | BUY | 2026-09-23 | $32K | — | Filing → |
| ACOG | BUY | 2026-09-16 | $1.1M | — | Filing → |